 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug LORAZEPAM: The question was whether LORAZEPAM increases or decreases the risk of bleeding. I consulted FDAHandler, and the response indicated that the LORAZEPAM label does not [0m
[34mmention an increased or decreased risk of bleeding in the adverse reactions and drug interactions sections. Therefore, there is no verified causal relationship between LORAZEPAM and an increased or [0m
[34mdecreased risk of bleeding according to the FDA label data.[0m
[1;34m2[0m[34m. Drug DIAZEPAM: DO-NOT-KNOW[0m

[34mThe question was whether DIAZEPAM increases or decreases the risk of bleeding. I attempted to obtain this information from FDAHandler using the `recipient_message` tool, but there was an issue with [0m
[34mthe tool, and I did not receive a response. Therefore, I cannot provide an answer based on FDA label data, and my final answer is DO-NOT-KNOW.[0m
[1;34m3[0m[34m. Drug CLONAZEPAM: Clonazepam may increase the risk of bleeding, but this is an infrequent side effect, occurring in [0m[1;34m1[0m[34m/[0m[1;34m100[0m[34m to [0m[1;34m1[0m[34m/[0m[1;34m1000[0m[34m patients.[0m
[34m                ---------[0m
[34m                Does the benzodiazepine category of drugs increase the risk of[0m
[34m                bleeding, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data."[0m[32m,[0m
[32m      [0m[32m"Passage 2 does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue."[0m[32m,[0m
[32m      [0m[32m"Passage 3 states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in 1/100 to 1/1000 patients."[0m[32m,[0m
[32m      [0m[32m"Given the available information, there is no clear consensus across the benzodiazepine category as a whole. One drug has no verified effect, information is missing for another, and one may [0m
[32mincrease the risk of bleeding infrequently."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect on the risk of bleeding for the benzodiazepine category of drugs as a whole."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data."[0m[34m,[0m
[34m      [0m[34m"Passage 2 does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue."[0m[34m,[0m
[34m      [0m[34m"Passage 3 states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in 1/100 to 1/1000 patients."[0m[34m,[0m
[34m      [0m[34m"Given the available information, there is no clear consensus across the benzodiazepine category as a whole. One drug has no verified effect, information is missing for another, and one may [0m
[34mincrease the risk of bleeding infrequently."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect on the risk of bleeding for the benzodiazepine category of drugs as a whole."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients.[0m
[1;31m4[0m[31m. Given the available information, there is no clear consensus across the benzodiazepine category as a whole. One drug has no verified effect, information is missing for another, and one may increase[0m
[31mthe risk of bleeding infrequently.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect on the risk of bleeding for the benzodiazepine category of drugs as a whole.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided has a flaw in the conclusion. While it is correct that there is no verified causal relationship for lorazepam and missing information for diazepam, the [0m
[32mstatement that clonazepam may increase the risk of bleeding, even if infrequently, indicates that there is at least some evidence of an increased risk within the benzodiazepine category. Therefore, [0m
[32mthe conclusion should reflect that there is evidence of an increased risk, albeit with a low frequency, rather than stating there is no clear effect across the category as a whole."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided has a flaw in the conclusion. While it is correct that there is no verified causal relationship for lorazepam and missing information for diazepam, the [0m
[34mstatement that clonazepam may increase the risk of bleeding, even if infrequently, indicates that there is at least some evidence of an increased risk within the benzodiazepine category. Therefore, [0m
[34mthe conclusion should reflect that there is evidence of an increased risk, albeit with a low frequency, rather than stating there is no clear effect across the category as a whole."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided has a flaw in the conclusion. While it is correct that there is no verified causal relationship for lorazepam and missing information for diazepam, the [0m
[31mstatement that clonazepam may increase the risk of bleeding, even if infrequently, indicates that there is at least some evidence of an increased risk within the benzodiazepine category. Therefore, [0m
[31mthe conclusion should reflect that there is evidence of an increased risk, albeit with a low frequency, rather than stating there is no clear effect across the category as a whole.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data."[0m[32m,[0m
[32m      [0m[32m"Passage 2 does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue."[0m[32m,[0m
[32m      [0m[32m"Passage 3 states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in 1/100 to 1/1000 patients."[0m[32m,[0m
[32m      [0m[32m"Given the available information, while there is no verified effect for LORAZEPAM and missing information for DIAZEPAM, the evidence that CLONAZEPAM may increase the risk of bleeding, even if [0m
[32minfrequently, suggests that there is at least some evidence of an increased risk within the benzodiazepine category."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The benzodiazepine category of drugs may increase the risk of bleeding, but this effect is infrequent based on the available evidence."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data."[0m[34m,[0m
[34m      [0m[34m"Passage 2 does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue."[0m[34m,[0m
[34m      [0m[34m"Passage 3 states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in 1/100 to 1/1000 patients."[0m[34m,[0m
[34m      [0m[34m"Given the available information, while there is no verified effect for LORAZEPAM and missing information for DIAZEPAM, the evidence that CLONAZEPAM may increase the risk of bleeding, even if [0m
[34minfrequently, suggests that there is at least some evidence of an increased risk within the benzodiazepine category."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The benzodiazepine category of drugs may increase the risk of bleeding, but this effect is infrequent based on the available evidence."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the benzodiazepine category of drugs increase the risk of bleeding, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that for LORAZEPAM, there is no verified causal relationship between the drug and an increased or decreased risk of bleeding according to FDA label data.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m does not provide any information regarding DIAZEPAM and its effects on bleeding risk due to a tool issue.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m states that CLONAZEPAM may increase the risk of bleeding, but this is an infrequent side effect, occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients.[0m
[1;31m4[0m[31m. Given the available information, while there is no verified effect for LORAZEPAM and missing information for DIAZEPAM, the evidence that CLONAZEPAM may increase the risk of bleeding, even if [0m
[31minfrequently, suggests that there is at least some evidence of an increased risk within the benzodiazepine category.[0m
[31m        -----[0m
[31m        Final answer: The benzodiazepine category of drugs may increase the risk of bleeding, but this effect is infrequent based on the available evidence.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The revised reasoning is correct. It acknowledges the evidence of an increased risk of bleeding with clonazepam, even if it is infrequent, and does not overgeneralize the absence of [0m
[32mevidence for lorazepam or the missing information for diazepam to the entire benzodiazepine category. The conclusion appropriately reflects the evidence provided, indicating a potential increase in [0m
[32mthe risk of bleeding associated with benzodiazepines, with the caveat that the effect is not common."[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"feedback"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The revised reasoning is correct. It acknowledges the evidence of an increased risk of bleeding with clonazepam, even if it is infrequent, and does not overgeneralize the absence of [0m
[34mevidence for lorazepam or the missing information for diazepam to the entire benzodiazepine category. The conclusion appropriately reflects the evidence provided, indicating a potential increase in [0m
[34mthe risk of bleeding associated with benzodiazepines, with the caveat that the effect is not common."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The revised reasoning is correct. It acknowledges the evidence of an increased risk of bleeding with clonazepam, even if it is infrequent, and does not overgeneralize the absence of [0m
[31mevidence for lorazepam or the missing information for diazepam to the entire benzodiazepine category. The conclusion appropriately reflects the evidence provided, indicating a potential increase in [0m
[31mthe risk of bleeding associated with benzodiazepines, with the caveat that the effect is not common.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"increase"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.6[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.01[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Based on the evidence provided, CLONAZEPAM, a benzodiazepine, may increase the risk of bleeding, but this is an infrequent side effect [0m[32m([0m[32m1/100 to 1/1000 patients[0m[32m)[0m[32m. For LORAZEPAM, [0m
[32mthere is no verified causal relationship with bleeding risk according to FDA label data, and there is missing information for DIAZEPAM. Therefore, while there is some evidence of an increased risk [0m
[32mwithin the benzodiazepine category, it is based on a single drug and is not a common effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-bleeding-benzodiazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
